MFH
MCID: MLG065
MIFTS: 36

Malignant Fibroxanthoma (MFH) malady

Categories: Cancer diseases

Aliases & Classifications for Malignant Fibroxanthoma

Aliases & Descriptions for Malignant Fibroxanthoma:

Name: Malignant Fibroxanthoma 12 14
Fibrous Histiocytoma, Malignant 12
Histiocytoma, Malignant Fibrous 42
Malignant Fibrous Histiocytoma 69
Fibroxanthosarcoma 12
Mfh 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1907
MeSH 42 D051677
NCIt 47 C4247
UMLS 69 C0334463

Summaries for Malignant Fibroxanthoma

MalaCards based summary : Malignant Fibroxanthoma, also known as fibrous histiocytoma, malignant, is related to sarcoma and fibrosarcoma. An important gene associated with Malignant Fibroxanthoma is SERPINA3 (Serpin Family A Member 3), and among its related pathways/superpathways are Innate Immune System and Glioma. The drugs Doxorubicin and Ifosfamide have been mentioned in the context of this disorder. Related phenotypes are neoplasm and digestive/alimentary

Related Diseases for Malignant Fibroxanthoma

Diseases related to Malignant Fibroxanthoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 87)
id Related Disease Score Top Affiliating Genes
1 sarcoma 29.7 CREB3L2 KIT
2 fibrosarcoma 29.6 CREB3L2 KIT MYOD1
3 inflammatory mfh 11.9
4 undifferentiated pleomorphic sarcoma 11.3
5 malignant skin fibrous histiocytoma 11.2
6 fibrous histiocytoma 10.5
7 appendicitis 10.3 LYZ SERPINA1
8 rommen mueller sybert syndrome 10.3 MDM2 TP53
9 mixed type rhabdomyosarcoma 10.3 MB MYOD1
10 acute mountain sickness 10.3 MDM2 TP53
11 intrahepatic bile duct cystadenoma 10.2 MB MYOD1
12 transitional cell carcinoma 10.2 MB MYOD1
13 ovarian cystadenoma 10.2 MB MYOD1
14 choriodal dystrophy, central areolar 2 10.2 LYZ SERPINA1
15 focal epithelial hyperplasia 10.2 MDM2 SERPINA1 SERPINA3
16 botryoid rhabdomyosarcoma 10.2 KIT MYOD1
17 scarlet fever 10.2 MDM2 TP53
18 ribbing disease 10.2 MDM2 PTPRC
19 bile duct rhabdomyosarcoma 10.2 MB MYOD1
20 testis sarcoma 10.2 KIT MYOD1
21 amelogenesis imperfecta-gingival hyperplasia syndrome 10.2 MDM2 MYOD1 SERPINA3
22 acromegaly 10.2 LYZ SERPINA3
23 verruciform xanthoma of skin 10.1 MB MYOD1 TP53
24 palmoplantar keratosis 10.1 MB MDM2 TP53
25 endometrial squamous cell carcinoma 10.1 MDM2 TP53
26 rhabdomyosarcoma 2, alveolar 10.1 MB MDM2 MYOD1
27 childhood medulloblastoma 10.1 MB MYOD1 TP53
28 bone leiomyosarcoma 10.1 MDM2 PTPRC
29 rhabdoid cancer 10.1 KIT PTPRC
30 prostate rhabdomyosarcoma 10.1 MB MYOD1 TP53
31 orbit embryonal rhabdomyosarcoma 10.1 KIT MYOD1
32 van regemorter pierquin vamos syndrome 10.1 KIT MB MDM2
33 arthus reaction 10.1 KIT MB TP53
34 embryonal extrahepatic bile duct rhabdomyosarcoma 10.1 MB MDM2 MYOD1
35 adenosquamous colon carcinoma 10.1 LYZ PTPRC
36 acantholytic squamous cell skin carcinoma 10.1 CREB3L2 MB TP53
37 cecum adenoma 10.1 KIT MDM2 TP53
38 juvenile xanthogranuloma 10.1 MFHAS1 MYOD1 SERPINA3
39 extraosseous ewing's sarcoma 10.1 KIT MB TP53
40 glaucoma iridogoniodysgenesia 10.1 CD68 MB
41 posterior uveitis 10.1 CD68 SERPINA1
42 linitis plastica 10.1 CD68 TP53
43 vulvar vestibulitis syndrome 10.1 CD68 MB
44 progressive external ophthalmoplegia with mitochondrial dna deletions, autosomal dominant 3 10.1 KIT MDM2 TP53
45 kidney rhabdoid cancer 10.1 KIT LYZ SERPINA1 SERPINA3
46 demyelinating disease 10.1 CD68 LYZ
47 brown-vialetto-van laere syndrome 10.1 KIT PTPRC TP53
48 malignant pleural solitary fibrous tumor 10.0 KIT MB TP53
49 plexopathy 10.0 MB PTPRC
50 chondroid lipoma 10.0 CD68 KIT

Graphical network of the top 20 diseases related to Malignant Fibroxanthoma:



Diseases related to Malignant Fibroxanthoma

Symptoms & Phenotypes for Malignant Fibroxanthoma

MGI Mouse Phenotypes related to Malignant Fibroxanthoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.87 FOXO4 KIT LYZ MDM2 MYOD1 PTPRC
2 digestive/alimentary MP:0005381 9.85 TP53 CREB3L2 KIT LYZ MDM2 PTPRC
3 no phenotypic analysis MP:0003012 9.8 PTPRC TP53 CD68 KIT LYZ MDM2
4 normal MP:0002873 9.7 FOXO4 KIT LYZ MDM2 MYOD1 PTPRC
5 respiratory system MP:0005388 9.43 KIT LYZ MB MYOD1 PTPRC TP53
6 skeleton MP:0005390 9.23 CD68 CREB3L2 KIT LYZ MDM2 MYOD1

Drugs & Therapeutics for Malignant Fibroxanthoma

Drugs for Malignant Fibroxanthoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 106)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
2
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
3
Mechlorethamine Approved Phase 3,Phase 2,Phase 1 51-75-2 4033
4
Dacarbazine Approved, Investigational Phase 3,Phase 2 4342-03-4 5351166
5
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
6
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
7
Dactinomycin Approved Phase 3 50-76-0 2019 457193
8
Epirubicin Approved Phase 3 56420-45-2 41867
9
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
10
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
11
Lenograstim Approved Phase 3,Phase 2 135968-09-1
12
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
13
Trabectedin Approved, Investigational Phase 3,Phase 2 114899-77-3 108150
14
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
15
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
16 Alkylating Agents Phase 3,Phase 2,Phase 1
17 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
18 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
19 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
20 Isophosphamide mustard Phase 3,Phase 2,Phase 1
21 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
22 Anti-Infective Agents Phase 3,Phase 2,Phase 1
23 Antiviral Agents Phase 3,Phase 2,Phase 1
24 Antimitotic Agents Phase 3,Phase 2,Phase 1
25 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
26 Antirheumatic Agents Phase 3,Phase 2,Phase 1
27 Etoposide phosphate Phase 3,Phase 2
28 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
29 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
30 Antimetabolites Phase 3,Phase 2,Phase 1
31 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
32
Indinavir Approved Phase 2 150378-17-9 5362440
33
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
34
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
35
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
36
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
37
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
38
Everolimus Approved Phase 1, Phase 2 159351-69-6 6442177
39
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
40
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030 46835353
41
Bevacizumab Approved, Investigational Phase 2 216974-75-3
42
Paclitaxel Approved, Vet_approved Phase 1, Phase 2 33069-62-4 36314
43
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
44
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
45
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4
46
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
47
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
48
Nicotinamide Approved, Nutraceutical Phase 2 98-92-0 936
49
leucovorin Approved, Nutraceutical Phase 2 58-05-9 54575, 6560146 143
50
Camptothecin Experimental Phase 2 7689-03-4

Interventional clinical trials:

(show top 50) (show all 62)
id Name Status NCT ID Phase
1 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3
2 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Unknown status NCT00346164 Phase 3
3 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3
4 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3
5 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3
6 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3
7 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
8 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3
9 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3
10 Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy Recruiting NCT01710176 Phase 3
11 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Recruiting NCT02180867 Phase 2, Phase 3
12 Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma Recruiting NCT01344018 Phase 3
13 A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma Active, not recruiting NCT02451943 Phase 3
14 Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma Active, not recruiting NCT00423618 Phase 3
15 Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3
16 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2
17 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2
18 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2
19 Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma Completed NCT00031915 Phase 2
20 Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma Completed NCT00400569 Phase 2
21 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2
22 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2
23 Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung Completed NCT00503295 Phase 2
24 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2
25 AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2
26 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Completed NCT00112463 Phase 2
27 Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans or Giant Cell Fibroblastoma Completed NCT00085475 Phase 2
28 Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00064220 Phase 2
29 Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma Completed NCT00949325 Phase 1, Phase 2
30 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2
31 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2
32 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2
33 Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma Completed NCT00053794 Phase 2
34 Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00041249 Phase 2
35 Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00041236 Phase 2
36 Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes Completed NCT00887809 Phase 2
37 Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma Recruiting NCT02601209 Phase 1, Phase 2
38 Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Recruiting NCT02584309 Phase 2
39 Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma Recruiting NCT01532687 Phase 2
40 Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes Recruiting NCT02815995 Phase 2
41 Autologous Dendritic Cell Vaccine Loaded With Allogeneic Tumor Lysate Expression of Cancer Testis Antigens in Patients With Soft Tissue Sarcoma Recruiting NCT01883518 Phase 1, Phase 2
42 To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors Recruiting NCT01962103 Phase 1, Phase 2
43 A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma Active, not recruiting NCT00667342 Phase 2
44 Alisertib in Treating Patients With Advanced or Metastatic Sarcoma Active, not recruiting NCT01653028 Phase 2
45 Pembrolizumab and Gemcitabine Chemotherapy in Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma Not yet recruiting NCT03123276 Phase 1, Phase 2
46 Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery Not yet recruiting NCT02923778 Phase 2
47 Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) Terminated NCT01418001 Phase 1, Phase 2
48 Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Stage IB, Stage II, or Stage III Soft Tissue Sarcoma Terminated NCT00740597 Phase 2
49 Celecoxib and Radiation Therapy in Treating Patients With Stage II or Stage III Soft Tissue Sarcoma of the Arm, Hand, Leg, or Foot That Has Been Removed by Surgery Completed NCT00450736 Phase 1
50 Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma Completed NCT00720174 Phase 1

Search NIH Clinical Center for Malignant Fibroxanthoma

Cochrane evidence based reviews: histiocytoma, malignant fibrous

Genetic Tests for Malignant Fibroxanthoma

Anatomical Context for Malignant Fibroxanthoma

Publications for Malignant Fibroxanthoma

Articles related to Malignant Fibroxanthoma:

id Title Authors Year
1
Malignant fibroxanthoma: a sarcoma of the vulva. ( 4704007 )
1973
2
Fibrosarcoma (malignant fibroxanthoma) involving conjunctiva and ciliary body. ( 5053693 )
1972
3
Ultrastructure of a fibroxanthosarcoma (malignant fibroxanthoma). ( 4105302 )
1971
4
Malignant fibroxanthoma (malignant histiocytoma): an ill-defined histologic entity with unpredictable biologic behavior. Report of a case with long-term survival. ( 4248417 )
1970
5
Metastasizing retroperitoneal fibroxanthoma (malignant fibroxanthoma). ( 5506607 )
1970

Variations for Malignant Fibroxanthoma

Copy number variations for Malignant Fibroxanthoma from CNVD:

7 (show all 41)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 18958 1 148000000 153300000 Gain Malignant fibrous histiocytomas
2 27753 1 212100000 222100000 Loss Malignant fibrous histiocytomas
3 33593 1 46500000 56200000 Gain Malignant fibrous histiocytomas
4 35188 1 60900000 69500000 Gain Malignant fibrous histiocytomas
5 37769 1 94500000 99400000 Gain Malignant fibrous histiocytomas
6 39415 10 114900000 121700000 Loss Malignant fibrous histiocytomas
7 50207 11 115400000 134452384 Loss Malignant fibrous histiocytomas
8 59633 11 76700000 85300000 Loss Malignant fibrous histiocytomas
9 60562 11 87900000 96700000 Loss Malignant fibrous histiocytomas
10 69083 12 5300000 14800000 Gain Malignant fibrous histiocytomas
11 76673 13 34700000 48900000 Loss Malignant fibrous histiocytomas
12 78011 13 48900000 57600000 Loss Malignant fibrous histiocytomas
13 86677 14 64000000 88900000 Gain Malignant fibrous histiocytomas
14 88587 14 92800000 106368585 Gain Malignant fibrous histiocytomas
15 101715 16 45500000 54500000 Loss Malignant fibrous histiocytomas
16 103579 16 6300000 10300000 Loss Malignant fibrous histiocytomas
17 107007 17 11200000 15900000 Gain Malignant fibrous histiocytomas
18 107027 17 11200000 22100000 Gain Malignant fibrous histiocytomas
19 107535 17 15900000 22100000 Gain Malignant fibrous histiocytomas
20 112060 17 37800000 44800000 Gain Malignant fibrous histiocytomas
21 119810 18 17300000 23300000 Gain Malignant fibrous histiocytomas
22 122735 18 59800000 76117153 Loss Malignant fibrous histiocytomas
23 127802 19 37100000 47800000 Gain Malignant fibrous histiocytomas
24 134297 2 1 12800000 Loss Malignant fibrous histiocytomas
25 142547 2 225800000 237000000 Loss Malignant fibrous histiocytomas
26 154853 20 49200000 54400000 Gain Malignant fibrous histiocytomas
27 163375 22 27900000 35900000 Gain Malignant fibrous histiocytomas
28 163745 22 30500000 39300000 Gain Malignant fibrous histiocytomas
29 164763 22 39300000 49691432 Loss Malignant fibrous histiocytomas
30 178974 3 83700000 89400000 Gain Malignant fibrous histiocytomas
31 187572 4 52400000 59200000 Gain Malignant fibrous histiocytomas
32 192956 5 121500000 143100000 Loss Malignant fibrous histiocytomas
33 198017 5 18500000 23300000 Gain Malignant fibrous histiocytomas
34 214607 6 63500000 75900000 Gain Malignant fibrous histiocytomas
35 221899 7 147500000 158821424 Loss Malignant fibrous histiocytomas
36 225328 7 4500000 7200000 Gain Malignant fibrous histiocytomas
37 226671 7 61100000 71800000 Gain Malignant fibrous histiocytomas
38 237234 8 2200000 19100000 Loss Malignant fibrous histiocytomas
39 244141 8 93500000 99100000 Gain Malignant fibrous histiocytomas
40 250775 9 2200000 9000000 Loss Malignant fibrous histiocytomas
41 255895 9 86100000 113900000 Gain Malignant fibrous histiocytomas

Expression for Malignant Fibroxanthoma

Search GEO for disease gene expression data for Malignant Fibroxanthoma.

Pathways for Malignant Fibroxanthoma

GO Terms for Malignant Fibroxanthoma

Biological processes related to Malignant Fibroxanthoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 neutrophil degranulation GO:0043312 9.55 CD68 LYZ PTPRC SERPINA1 SERPINA3
2 cellular response to gamma radiation GO:0071480 9.37 MDM2 TP53
3 positive regulation of cell cycle arrest GO:0071158 9.32 FOXO4 TP53
4 positive regulation of protein export from nucleus GO:0046827 9.26 MDM2 TP53
5 response to water-immersion restraint stress GO:1990785 8.96 FOXO4 MDM2
6 cellular response to actinomycin D GO:0072717 8.62 MDM2 TP53

Molecular functions related to Malignant Fibroxanthoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.55 FOXO4 LYZ MDM2 SERPINA1 TP53
2 enzyme binding GO:0019899 9.26 FOXO4 MDM2 MYOD1 TP53
3 protease binding GO:0002020 8.8 KIT SERPINA1 TP53

Sources for Malignant Fibroxanthoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....